Melatonin

Melatonin
Names
IUPAC name
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
Other names
5-Methoxy-N-acetyltryptamine; N-Acetyl-5-methoxytryptamine; NSC-113928
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.000.725
EC Number
  • 200-797-7
KEGG
CompTox Dashboard (EPA)
  • InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)
    Key: DRLFMBDRBRZALE-UHFFFAOYSA-N
  • CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
Properties
C13H16N2O2
Molar mass 232.281 g/mol
Melting point 117
Pharmacology
Pharmacokinetics:
20–50 minutes[1][2][3]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Not to be confused with melanin. For the album, see Melatonin (album).

Melatonin is a natural product found in plants and animals. It is primarily known in animals as a hormone released by the pineal gland in the brain at night, and has long been associated with control of the sleep–wake cycle.[2][4]

In vertebrates, melatonin is involved in synchronizing circadian rhythms, including sleep–wake timing and blood pressure regulation, and in control of seasonal rhythmicity including reproduction, fattening, moulting and hibernation.[5] Many of its effects are through activation of the melatonin receptors, while others are due to its role as an antioxidant.[6][7][8] In plants, it functions to defend against oxidative stress.[9] It is also present in various foods.[10]

Melatonin was discovered in 1958.[2]

In addition to its role as a natural hormone, melatonin is used as a dietary supplement and medication in the treatment of sleep disorders such as insomnia and circadian rhythm sleep disorders; for information on melatonin as a supplement and medication, see the melatonin (supplement/medication) article.

Biological activity

In humans, melatonin is a full agonist of melatonin receptor 1 (picomolar binding affinity) and melatonin receptor 2 (nanomolar binding affinity), both of which belong to the class of G-protein coupled receptors (GPCRs).[11][12] Melatonin receptors 1 and 2 are both Gi/o-coupled GPCRs, although melatonin receptor 1 is also Gq-coupled.[11] Melatonin also acts as a high-capacity free radical scavenger within mitochondria which also promotes the expression of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase via signal transduction through melatonin receptors.[13][11][14][15][16][17]

Biological functions
When eyes receive light from the sun, the pineal gland's production of melatonin is inhibited and the hormones produced keep the human awake. When the eyes do not receive light, melatonin is produced in the pineal gland and the human becomes tired.

Circadian rhythm

In animals, melatonin plays an important role in the regulation of sleep–wake cycles.[18] Human infants' melatonin levels become regular in about the third month after birth, with the highest levels measured between midnight and 8:00 am.[19] Human melatonin production decreases as a person ages.[20] Also, as children become teenagers, the nightly schedule of melatonin release is delayed, leading to later sleeping and waking times.[21]

Antioxidant

Melatonin was first reported as a potent antioxidant and free radical scavenger in 1993.[22] In vitro, melatonin acts as a direct scavenger of oxygen radicals including OH•, O2−•, and the reactive nitrogen species NO•.[23][24] In plants, melatonin works with other antioxidants to improve the overall effectiveness of each antioxidant.[24] Melatonin has been proven to be twice as active as vitamin E, believed to be the most effective lipophilic antioxidant.[25] Via signal transduction through melatonin receptors, melatonin promotes the expression of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase.[13][11]

Melatonin occurs at high concentrations within mitochondrial fluid which greatly exceed the plasma concentration of melatonin.[14][15][16] Due to its capacity for free radical scavenging, indirect effects on the expression of antioxidant enzymes, and its significant concentrations within mitochondria, a number of authors have indicated that melatonin has an important physiological function as a mitochondrial antioxidant.[13][14][15][16][17]

The melatonin metabolites produced via the reaction of melatonin with reactive oxygen species or reactive nitrogen species also react with and reduce free radicals.[11][17] Melatonin metabolites generated from redox reactions include cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), and N1-acetyl-5-methoxykynuramine (AMK).[11][17]

Immune system

While it is known that melatonin interacts with the immune system,[26][27] the details of those interactions are unclear. An anti-inflammatory effect seems to be the most relevant. There have been few trials designed to judge the effectiveness of melatonin in disease treatment. Most existing data are based on small, incomplete trials. Any positive immunological effect is thought to be the result of melatonin acting on high-affinity receptors (MT1 and MT2) expressed in immunocompetent cells. In preclinical studies, melatonin may enhance cytokine production,[28] and by doing this, counteract acquired immunodeficiences. Some studies also suggest that melatonin might be useful fighting infectious disease[29] including viral, such as HIV, and bacterial infections, and potentially in the treatment of cancer.

Weight regulation

A possible mechanism by which melatonin may regulate weight gain is through its inhibitory effect on leptin.[30] Leptin acts as a long-term indicator of energy status in the human body.[31] By suppressing leptin's actions outside of waking hours, melatonin may help restore leptin sensitivity during the daytime by alleviating leptin resistance.[30][32]

Biochemistry

Biosynthesis
Overview of melatonin biosynthesis

In animals, biosynthesis of melatonin occurs through hydroxylation, decarboxylation, acetylation and a methylation starting with L-tryptophan.[33] L-tryptophan is produced in the shikimate pathway from chorismate or is acquired from protein catabolism. First L-tryptophan is hydroxylated on the indole ring by tryptophan hydroxylase to produce 5-hydroxytryptophan. This intermediate (5-HTP) is decarboxylated by pyridoxal phosphate and 5-hydroxytryptophan decarboxylase to produce serotonin.

Serotonin is itself an important neurotransmitter, but is also converted into N-acetylserotonin by serotonin N-acetyltransferase with acetyl-CoA.[34] Hydroxyindole O-methyltransferase and S-adenosyl methionine convert N-acetylserotonin into melatonin through methylation of the hydroxyl group.[34]

In bacteria, protists, fungi, and plants, melatonin is synthesized indirectly with tryptophan as an intermediate product of the shikimate pathway. In these cells, synthesis starts with D-erythrose 4-phosphate and phosphoenolpyruvate, and in photosynthetic cells with carbon dioxide. The rest of the synthesizing reactions are similar, but with slight variations in the last two enzymes.[35][36]

It has been hypothesized that melatonin is made in the mitochondria and chloroplasts.[37]

Mechanism
Mechanism of melatonin biosynthesis.

In order to hydroxylate L-tryptophan, the cofactor tetrahydrobiopterin (THB) must first react with oxygen and the active site iron of tryptophan hydroxylase. This mechanism is not well understood, but two mechanisms have been proposed:

1. A slow transfer of one electron from the THB to O2 could produce a superoxide which could recombine with the THB radical to give 4a-peroxypterin. 4a-peroxypterin could then react with the active site iron (II) to form an iron-peroxypterin intermediate or directly transfer an oxygen atom to the iron.

2. O2 could react with the active site iron (II) first, producing iron (III) superoxide which could then react with the THB to form an iron-peroxypterin intermediate.

Iron (IV) oxide from the iron-peroxypterin intermediate is selectively attacked by a double bond to give a carbocation at the C5 position of the indole ring. A 1.2-shift of the hydrogen and then a loss of one of the two hydrogen atoms on C5 reestablishes aromaticity to furnish 5-hydroxy-L-tryptophan.[38]

A decarboxylase with cofactor pyridoxal phosphate (PLP) removes CO2 from 5-hydroxy-L-tryptophan to produce 5-hydroxytryptamine.[39] PLP forms an imine with the amino acid derivative. The amine on the pyridine is protonated and acts as an electron sink, enabling the breaking of the C-C bond and releasing CO2. Protonation of the amine from tryptophan restores the aromaticity of the pyridine ring and then imine is hydrolyzed to produce 5-hydroxytryptamine and PLP.[40]

It has been proposed that histidine residue His122 of serotonin N-acetyl transferase is the catalytic residue that deprotonates the primary amine of 5-hydroxytryptamine, which allows the lone pair on the amine to attack acetyl-CoA, forming a tetrahedral intermediate. The thiol from coenzyme A serves as a good leaving group when attacked by a general base to give N-acetylserotonin.[41]

N-Acetylserotonin is methylated at the hydroxyl position by S-adenosyl methionine (SAM) to produce S-adenosyl homocysteine (SAH) and melatonin.[40][42]

Regulation

In vertebrates, melatonin secretion is regulated by activation of the beta-1 adrenergic receptor by norepinephrine.[43] Norepinephrine elevates the intracellular cAMP concentration via beta-adrenergic receptors and activates the cAMP-dependent protein kinase A (PKA). PKA phosphorylates the penultimate enzyme, the arylalkylamine N-acetyltransferase (AANAT). On exposure to (day)light, noradrenergic stimulation stops and the protein is immediately destroyed by proteasomal proteolysis.[44] Production of melatonin is again started in the evening at the point called the dim-light melatonin onset.

Blue light, principally around 460–480 nm, suppresses melatonin biosynthesis,[45] proportional to the light intensity and length of exposure. Until recent history, humans in temperate climates were exposed to few hours of (blue) daylight in the winter; their fires gave predominantly yellow light.[46] The incandescent light bulb widely used in the 20th century produced relatively little blue light.[47] Light containing only wavelengths greater than 530 nm does not suppress melatonin in bright-light conditions.[48] Wearing glasses that block blue light in the hours before bedtime may decrease melatonin loss.[49] Use of blue-blocking goggles the last hours before bedtime has also been advised for people who need to adjust to an earlier bedtime, as melatonin promotes sleepiness.[50]

Metabolism

Melatonin has an elimination half-life of 20 to 50 minutes.[1][2][3]

Measurement

For research as well as clinical purposes, melatonin concentration in humans can be measured either from the saliva or blood plasma.[51]

Medical use

Melatonin is used as a medication in the treatment of sleep disorders such as insomnia and circadian rhythm sleep disorders like delayed sleep phase disorder, jet lag disorder, and shift work disorder.[52] Besides melatonin, certain synthetic melatonin receptor agonists like ramelteon, tasimelteon, and agomelatine are also used in medicine.[53][54]

As a dietary supplement

Melatonin is sold as a dietary supplement in countries where it is not a scheduled drug. In the US, melatonin is considered a nutritional supplement and is exempt from harsher FDA regulation relative to scheduled or prescription-only medication.[55] As much as 70% of surveyed melatonin supplements on the US market in 2017 contained less than 10% of their advertised melatonin content.[56] Some supplements contained more than 400% of their advertised melatonin content.[56]

There is evidence to suggest that the typical advertised dose of most melatonin supplements (more than 1mg) are excessive for the treatment of insomnia and may even be detrimental to overall sleep quality.[57][58] 4mg of controlled release melatonin has been found to cause excessive melatonin levels upon waking (>50pg/ml), possibly contributing to lethargy in the morning.[57] By contrast, 0.4mg of controlled release melatonin was not found to cause elevated melatonin levels upon waking.[57]

History

Melatonin was first discovered in connection to the mechanism by which some amphibians and reptiles change the color of their skin.[59][60] As early as 1917, Carey Pratt McCord and Floyd P. Allen discovered that feeding extract of the pineal glands of cows lightened tadpole skin by contracting the dark epidermal melanophores.[61][62]

In 1958, dermatology professor Aaron B. Lerner and colleagues at Yale University, in the hope that a substance from the pineal might be useful in treating skin diseases, isolated the hormone from bovine pineal gland extracts and named it melatonin.[63] In the mid-70s Lynch et al. demonstrated that the production of melatonin exhibits a circadian rhythm in human pineal glands.[64]

In other species

Other animals

In vertebrates, melatonin is produced in darkness, thus usually at night, by the pineal gland, a small endocrine gland[65] located in the center of the brain but outside the blood–brain barrier. Light/dark information reaches the suprachiasmatic nuclei from retinal photosensitive ganglion cells of the eyes[66][67] rather than the melatonin signal (as was once postulated). Known as "the hormone of darkness", the onset of melatonin at dusk promotes activity in nocturnal (night-active) animals and sleep in diurnal ones including humans.[68]

Many animals use the variation in duration of melatonin production each day as a seasonal clock.[69] In animals including humans,[70] the profile of melatonin synthesis and secretion is affected by the variable duration of night in summer as compared to winter. The change in duration of secretion thus serves as a biological signal for the organization of daylength-dependent (photoperiodic) seasonal functions such as reproduction, behavior, coat growth, and camouflage coloring in seasonal animals.[70] In seasonal breeders that do not have long gestation periods and that mate during longer daylight hours, the melatonin signal controls the seasonal variation in their sexual physiology, and similar physiological effects can be induced by exogenous melatonin in animals including mynah birds[71] and hamsters.[72] Melatonin can suppress libido by inhibiting secretion of luteinizing hormone and follicle-stimulating hormone from the anterior pituitary gland, especially in mammals that have a breeding season when daylight hours are long. The reproduction of long-day breeders is repressed by melatonin and the reproduction of short-day breeders is stimulated by melatonin.

During the night, melatonin regulates leptin, lowering its levels.

Cetaceans have lost all the genes for melatonin synthesis as well as those for melatonin receptors.[73] This is thought to be related to their unihemispheric sleep pattern (one brain hemisphere at a time). Similar trends have been found in sirenians.[73]

Plants

Until its identification in plants in 1987, melatonin was for decades thought to be primarily an animal neurohormone. When melatonin was identified in coffee extracts in the 1970s, it was believed to be a byproduct of the extraction process. Subsequently, however, melatonin has been found in all plants that have been investigated. It is present in all the different parts of plants, including leaves, stems, roots, fruits, and seeds, in varying proportions.[9][74] Melatonin concentrations differ not only among plant species, but also between varieties of the same species depending on the agronomic growing conditions, varying from picograms to several micrograms per gram.[36][75] Notably high melatonin concentrations have been measured in popular beverages such as coffee, tea, wine, and beer, and crops including corn, rice, wheat, barley, and oats.[9] In some common foods and beverages, including coffee[9] and walnuts,[76] the concentration of melatonin has been estimated or measured to be sufficiently high to raise the blood level of melatonin above daytime baseline values.

Although a role for melatonin as a plant hormone has not been clearly established, its involvement in processes such as growth and photosynthesis is well established. Only limited evidence of endogenous circadian rhythms in melatonin levels has been demonstrated in some plant species and no membrane-bound receptors analogous to those known in animals have been described. Rather, melatonin performs important roles in plants as a growth regulator, as well as environmental stress protector. It is synthesized in plants when they are exposed to both biological stresses, for example, fungal infection, and nonbiological stresses such as extremes of temperature, toxins, increased soil salinity, drought, etc.[36][77][78]

Herbicide-induced oxidative stress has been experimentally mitigated in vivo in a high-melatonin transgenic rice.[79][80]

Fungal disease resistance is another role. Added melatonin increases resistance in Malus prunifolia against Diplocarpon mali.[80][81] Also acts as a growth inhibitor on fungal pathogens including Alternaria, Botrytis, and Fusarium spp. Decreases the speed of infection. As a seed treatment, protects Lupinus albus from fungi. Dramatically slows Pseudomonas syringae tomato DC3000 infecting Arabidopsis thaliana and infecting Nicotiana benthamiana.[81]

Fungi

Melatonin has been observed to reduce stress tolerance in Phytophthora infestans in plant-pathogen systems.[82]

Occurrence

Food products

Naturally-occurring melatonin has been reported in foods including tart cherries to about 0.17–13.46 ng/g,[83] bananas, plums, grapes, rice, cereals, herbs,[84] olive oil, wine,[85] and beer.[86] The consumption of milk and sour cherries may improve sleep quality.[87] When birds ingest melatonin-rich plant feed, such as rice, the melatonin binds to melatonin receptors in their brains.[88] When humans consume foods rich in melatonin, such as banana, pineapple, and orange, the blood levels of melatonin increase significantly.[89]

References
  1. "Melatonin". www.drugbank.ca. Retrieved 29 January 2019.
  2. Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (August 2017). "Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders" (PDF). Sleep Medicine Reviews. 34: 10–22. doi:10.1016/j.smrv.2016.06.005. hdl:20.500.11820/0e890bda-4b1d-4786-a907-a03b1580fd07. PMID 28648359.
  3. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP (2008). "Melatonergic drugs in clinical practice". Arzneimittelforschung. 58 (1): 1–10. doi:10.1055/s-0031-1296459. PMID 18368944.
  4. Faraone SV (2014). ADHD: Non-Pharmacologic Interventions, An Issue of Child and Adolescent Psychiatric Clinics of North America, E-Book. Elsevier Health Sciences. p. 888. ISBN 978-0-323-32602-5.
  5. Altun A, Ugur-Altun B (May 2007). "Melatonin: therapeutic and clinical utilization". International Journal of Clinical Practice. 61 (5): 835–45. doi:10.1111/j.1742-1241.2006.01191.x. PMID 17298593. S2CID 18050554.
  6. Boutin JA, Audinot V, Ferry G, Delagrange P (August 2005). "Molecular tools to study melatonin pathways and actions". Trends in Pharmacological Sciences. 26 (8): 412–9. doi:10.1016/j.tips.2005.06.006. PMID 15992934.
  7. Hardeland R (July 2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine. 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125. S2CID 46984486.
  8. Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S (June 2001). "Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system". Annals of the New York Academy of Sciences. 939 (1): 200–15. Bibcode:2001NYASA.939..200R. doi:10.1111/j.1749-6632.2001.tb03627.x. PMID 11462772. S2CID 20404509.
  9. Tan DX, Hardeland R, Manchester LC, Korkmaz A, Ma S, Rosales-Corral S, Reiter RJ (January 2012). "Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science". Journal of Experimental Botany. 63 (2): 577–97. doi:10.1093/jxb/err256. PMID 22016420.
  10. "Melatonin: Side Effects, Uses, Dosage (Kids/Adults)". Drugs.com. Retrieved 9 January 2019.
  11. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, et al. (September 2016). "Update on melatonin receptors: IUPHAR Review 20". British Journal of Pharmacology. 173 (18): 2702–25. doi:10.1111/bph.13536. PMC 4995287. PMID 27314810. Hence, one melatonin molecule and its associated metabolites could scavenge a large number of reactive species, and thus, the overall antioxidant capacity of melatonin is believed to be greater than that of other well‐known antioxidants, such as vitamin C and vitamin E, under in vitro or in vivo conditions (Gitto et al., 2001; Sharma and Haldar, 2006; Ortiz et al., 2013).
  12. "Melatonin receptors | G protein-coupled receptors | IUPHAR/BPS Guide to Pharmacology". www.guidetopharmacology.org. Retrieved 7 April 2017.
  13. Sharafati-Chaleshtori R, Shirzad H, Rafieian-Kopaei M, Soltani A (2017). "Melatonin and human mitochondrial diseases". Journal of Research in Medical Sciences. 22: 2. doi:10.4103/1735-1995.199092. PMC 5361446. PMID 28400824.
  14. Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B (November 2017). "Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas". Cellular and Molecular Life Sciences. 74 (21): 3863–3881. doi:10.1007/s00018-017-2609-7. PMID 28864909. S2CID 23820389. melatonin is specifically targeted to the mitochondria where it seems to function as an apex antioxidant ... The measurement of the subcellular distribution of melatonin has shown that the concentration of this indole in the mitochondria greatly exceeds that in the blood.
  15. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L (October 2016). "Melatonin as an antioxidant: under promises but over delivers". Journal of Pineal Research. 61 (3): 253–78. doi:10.1111/jpi.12360. PMID 27500468. S2CID 35435683. There is credible evidence to suggest that melatonin should be classified as a mitochondria-targeted antioxidant.
  16. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. (November 2015). "Melatonin: an ancient molecule that makes oxygen metabolically tolerable". Journal of Pineal Research. 59 (4): 403–19. doi:10.1111/jpi.12267. PMID 26272235. S2CID 24373303. While originally thought to be produced exclusively in and secreted from the vertebrate pineal gland [53], it is now known that the indole is present in many, perhaps all, vertebrate organs [54] and in organs of all plants that have been investigated [48, 55, 56]. That melatonin is not relegated solely to the pineal gland is also emphasized by the reports that it is present in invertebrates [57–59], which lack a pineal gland and some of which consist of only a single cell.
  17. Mayo JC, Sainz RM, González-Menéndez P, Hevia D, Cernuda-Cernuda R (November 2017). "Melatonin transport into mitochondria". Cellular and Molecular Life Sciences. 74 (21): 3927–3940. doi:10.1007/s00018-017-2616-8. PMID 28828619. S2CID 10920415.
  18. Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A (June 2016). "A Review of Melatonin, Its Receptors and Drugs". The Eurasian Journal of Medicine. 48 (2): 135–41. doi:10.5152/eurasianjmed.2015.0267. PMC 4970552. PMID 27551178.
  19. Ardura J, Gutierrez R, Andres J, Agapito T (2003). "Emergence and evolution of the circadian rhythm of melatonin in children". Hormone Research. 59 (2): 66–72. doi:10.1159/000068571. PMID 12589109. S2CID 41937922.
  20. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM (1986). "Human melatonin production decreases with age". Journal of Pineal Research. 3 (4): 379–88. doi:10.1111/j.1600-079X.1986.tb00760.x. PMID 3783419. S2CID 33664568.
  21. Hagenauer MH, Perryman JI, Lee TM, Carskadon MA (June 2009). "Adolescent changes in the homeostatic and circadian regulation of sleep". Developmental Neuroscience. 31 (4): 276–84. doi:10.1159/000216538. PMC 2820578. PMID 19546564.
  22. Tan DX, Chen LD, Poeggeler B, L Manchester C, Reiter RJ (1993). "Melatonin: a potent, endogenous hydroxyl radical scavenger". Endocr. J. 1: 57–60.
  23. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, Barlow-Walden LR (November 1994). "Melatonin—a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro". Annals of the New York Academy of Sciences. 738 (1): 419–20. Bibcode:1994NYASA.738..419P. doi:10.1111/j.1749-6632.1994.tb21831.x. PMID 7832450. S2CID 36383425.
  24. Arnao MB, Hernández-Ruiz J (May 2006). "The physiological function of melatonin in plants". Plant Signaling & Behavior. 1 (3): 89–95. doi:10.4161/psb.1.3.2640. PMC 2635004. PMID 19521488.
  25. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F (1994). "Melatonin: a peroxyl radical scavenger more effective than vitamin E". Life Sciences. 55 (15): PL271-6. doi:10.1016/0024-3205(94)00666-0. PMID 7934611.
  26. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (July 2005). "A review of the multiple actions of melatonin on the immune system". Endocrine. 27 (2): 189–200. doi:10.1385/ENDO:27:2:189. PMID 16217132. S2CID 21133107.
  27. Arushanian EB, Beĭer EV (2002). "[Immunotropic properties of pineal melatonin]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 65 (5): 73–80. PMID 12596522.
  28. Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernández-Montesinos R, Guerrero JM, Pozo D (May 2006). "The modulatory role of melatonin on immune responsiveness". Current Opinion in Investigational Drugs. 7 (5): 423–31. PMID 16729718.
  29. Maestroni GJ (March 2001). "The immunotherapeutic potential of melatonin". Expert Opinion on Investigational Drugs. 10 (3): 467–76. doi:10.1517/13543784.10.3.467. PMID 11227046. S2CID 6822594.
  30. Suriagandhi V, Nachiappan V (January 2022). "Protective Effects of Melatonin against Obesity-Induced by Leptin Resistance". Behavioural Brain Research. 417: 113598. doi:10.1016/j.bbr.2021.113598. PMID 34563600. S2CID 237603177.
  31. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS (January 2010). "Narrative review: the role of leptin in human physiology: emerging clinical applications". Annals of Internal Medicine. 152 (2): 93–100. doi:10.7326/0003-4819-152-2-201001190-00008. PMC 2829242. PMID 20083828.
  32. Buonfiglio D, Parthimos R, Dantas R, Cerqueira Silva R, Gomes G, Andrade-Silva J, et al. (2018). "Melatonin Absence Leads to Long-Term Leptin Resistance and Overweight in Rats". Frontiers in Endocrinology. 9: 122. doi:10.3389/fendo.2018.00122. PMC 5881424. PMID 29636725.
  33. "MetaCyc serotonin and melatonin biosynthesis".
  34. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C (April 2017). "Melatonin: Pharmacology, Functions and Therapeutic Benefits". Current Neuropharmacology. 15 (3): 434–443. doi:10.2174/1570159X14666161228122115. PMC 5405617. PMID 28503116.
  35. Bochkov DV, Sysolyatin SV, Kalashnikov AI, Surmacheva IA (January 2012). "Shikimic acid: review of its analytical, isolation, and purification techniques from plant and microbial sources". Journal of Chemical Biology. 5 (1): 5–17. doi:10.1007/s12154-011-0064-8. PMC 3251648. PMID 22826715.
  36. Hardeland R (February 2015). "Melatonin in plants and other phototrophs: advances and gaps concerning the diversity of functions". Journal of Experimental Botany. 66 (3): 627–46. doi:10.1093/jxb/eru386. PMID 25240067.
  37. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ (March 2013). "Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes". Journal of Pineal Research. 54 (2): 127–38. doi:10.1111/jpi.12026. PMID 23137057. S2CID 206140413.
  38. Roberts KM, Fitzpatrick PF (April 2013). "Mechanisms of tryptophan and tyrosine hydroxylase". IUBMB Life. 65 (4): 350–7. doi:10.1002/iub.1144. PMC 4270200. PMID 23441081.
  39. Sumi-Ichinose C, Ichinose H, Takahashi E, Hori T, Nagatsu T (March 1992). "Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis". Biochemistry. 31 (8): 2229–38. doi:10.1021/bi00123a004. PMID 1540578.
  40. Dewick PM (2002). Medicinal Natural Products. A Biosynthetic Approach (2nd ed.). Wiley. ISBN 978-0-471-49640-3.
  41. Hickman AB, Klein DC, Dyda F (January 1999). "Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2.5 A resolution suggests a catalytic mechanism". Molecular Cell. 3 (1): 23–32. doi:10.1016/S1097-2765(00)80171-9. PMID 10024876.
  42. Donohue SJ, Roseboom PH, Illnerova H, Weller JL, Klein DC (October 1993). "Human hydroxyindole-O-methyltransferase: presence of LINE-1 fragment in a cDNA clone and pineal mRNA". DNA and Cell Biology. 12 (8): 715–27. doi:10.1089/dna.1993.12.715. PMID 8397829.
  43. Nesbitt AD, Leschziner GD, Peatfield RC (September 2014). "Headache, drugs and sleep". Cephalalgia (Review). 34 (10): 756–66. doi:10.1177/0333102414542662. PMID 25053748. S2CID 33548757.
  44. Schomerus C, Korf HW (December 2005). "Mechanisms regulating melatonin synthesis in the mammalian pineal organ". Annals of the New York Academy of Sciences. 1057 (1): 372–83. Bibcode:2005NYASA1057..372S. doi:10.1196/annals.1356.028. PMID 16399907. S2CID 20517556.
  45. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, Rollag MD (August 2001). "Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor". The Journal of Neuroscience. 21 (16): 6405–12. doi:10.1523/JNEUROSCI.21-16-06405.2001. PMC 6763155. PMID 11487664.
  46. Holzman DC (January 2010). "What's in a color? The unique human health effect of blue light". Environmental Health Perspectives. 118 (1): A22-7. doi:10.1289/ehp.118-a22. PMC 2831986. PMID 20061218.
  47. "Recent News – Program of Computer Graphics". www.graphics.cornell.edu.
  48. Kayumov L, Casper RF, Hawa RJ, Perelman B, Chung SA, Sokalsky S, Shapiro CM (May 2005). "Blocking low-wavelength light prevents nocturnal melatonin suppression with no adverse effect on performance during simulated shift work". The Journal of Clinical Endocrinology and Metabolism. 90 (5): 2755–61. doi:10.1210/jc.2004-2062. PMID 15713707.
  49. "University of Houston study shows blue light glasses at night increase melatonin by 58%". designeroptics.com. Retrieved 26 August 2021.
  50. Burkhart K, Phelps JR (December 2009). "Amber lenses to block blue light and improve sleep: a randomized trial". Chronobiology International. 26 (8): 1602–12. doi:10.3109/07420520903523719. PMID 20030543. S2CID 145296760.
  51. Kennaway DJ (August 2019). "A critical review of melatonin assays: Past and present". Journal of Pineal Research. 67 (1): e12572. doi:10.1111/jpi.12572. PMID 30919486.
  52. Riha RL (November 2018). "The use and misuse of exogenous melatonin in the treatment of sleep disorders". Curr Opin Pulm Med. 24 (6): 543–548. doi:10.1097/MCP.0000000000000522. PMID 30148726. S2CID 52096729.
  53. Williams WP, McLin DE, Dressman MA, Neubauer DN (September 2016). "Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders". Pharmacotherapy. 36 (9): 1028–41. doi:10.1002/phar.1822. PMC 5108473. PMID 27500861.
  54. Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacol Rev. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID 29487083. S2CID 3578916.
  55. "Melatonin: What You Need To Know". NCCIH. Retrieved 4 September 2022.
  56. Grigg-Damberger MM, Ianakieva D (February 2017). "Poor Quality Control of Over-the-Counter Melatonin: What They Say Is Often Not What You Get". Journal of Clinical Sleep Medicine. 13 (2): 163–165. doi:10.5664/jcsm.6434. PMC 5263069. PMID 28095978.
  57. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS (May 2012). "Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults". Journal of Pineal Research. 52 (4): 437–445. doi:10.1111/j.1600-079X.2011.00958.x. PMC 3682489. PMID 22348451.
  58. Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N (February 2022). "Trends in Use of Melatonin Supplements Among US Adults, 1999-2018". JAMA. 327 (5): 483–485. doi:10.1001/jama.2021.23652. PMC 8808329. PMID 35103775.
  59. Filadelfi AM, Castrucci AM (May 1996). "Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates". Journal of Pineal Research. 20 (4): 175–86. doi:10.1111/j.1600-079X.1996.tb00256.x. PMID 8836950. S2CID 41959214.
  60. Sugden D, Davidson K, Hough KA, Teh MT (October 2004). "Melatonin, melatonin receptors and melanophores: a moving story". Pigment Cell Research. 17 (5): 454–60. doi:10.1111/j.1600-0749.2004.00185.x. PMID 15357831.
  61. Coates PM, Blackman MR, Cragg GM, Levine M, Moss J, White JD (2005). Encyclopedia of dietary supplements. New York, N.Y: Marcel Dekker. pp. 457–66. ISBN 978-0-8247-5504-1.
  62. McCord CP, Allen FP (January 1917). "Evidences associating pineal gland function with alterations in pigmentation". J Exp Zool. 23 (1): 206–24. doi:10.1002/jez.1400230108.
  63. Lerner AB, Case JD, Takahashi Y (July 1960). "Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands". The Journal of Biological Chemistry. 235 (7): 1992–7. doi:10.1016/S0021-9258(18)69351-2. PMID 14415935.
  64. Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH (January 1975). "Daily rhythm in human urinary melatonin". Science. 187 (4172): 169–71. Bibcode:1975Sci...187..169L. doi:10.1126/science.1167425. PMID 1167425.
  65. Reiter RJ (May 1991). "Pineal melatonin: cell biology of its synthesis and of its physiological interactions". Endocrine Reviews. 12 (2): 151–80. doi:10.1210/edrv-12-2-151. PMID 1649044. S2CID 3219721.
  66. Richardson GS (2005). "The human circadian system in normal and disordered sleep". The Journal of Clinical Psychiatry. 66 (Suppl 9): 3–9, quiz 42–3. PMID 16336035.
  67. Perreau-Lenz S, Pévet P, Buijs RM, Kalsbeek A (January 2004). "The biological clock: the bodyguard of temporal homeostasis". Chronobiology International. 21 (1): 1–25. doi:10.1081/CBI-120027984. PMID 15129821. S2CID 42725506.
  68. Foster RG (June 2020). "Sleep, circadian rhythms and health". Interface Focus. 10 (3): 20190098. doi:10.1098/rsfs.2019.0098. PMC 7202392. PMID 32382406.
  69. Lincoln GA, Andersson H, Loudon A (October 2003). "Clock genes in calendar cells as the basis of annual timekeeping in mammals—a unifying hypothesis". The Journal of Endocrinology. 179 (1): 1–13. doi:10.1677/joe.0.1790001. PMID 14529560.
  70. Arendt J, Skene DJ (February 2005). "Melatonin as a chronobiotic". Sleep Medicine Reviews. 9 (1): 25–39. doi:10.1016/j.smrv.2004.05.002. PMID 15649736. Exogenous melatonin has acute sleepiness-inducing and temperature-lowering effects during 'biological daytime', and when suitably timed (it is most effective around dusk and dawn), it will shift the phase of the human circadian clock (sleep, endogenous melatonin, core body temperature, cortisol) to earlier (advance phase shift) or later (delay phase shift) times.
  71. Chaturvedi CM (1984). "Effect of Melatonin on the Adrenl and Gonad of the Common Mynah Acridtheres tristis". Australian Journal of Zoology. 32 (6): 803–09. doi:10.1071/ZO9840803.
  72. Chen HJ (July 1981). "Spontaneous and melatonin-induced testicular regression in male golden hamsters: augmented sensitivity of the old male to melatonin inhibition". Neuroendocrinology. 33 (1): 43–6. doi:10.1159/000123198. PMID 7254478.
  73. Huelsmann M, Hecker N, Springer MS, Gatesy J, Sharma V, Hiller M (September 2019). "Genes lost during the transition from land to water in cetaceans highlight genomic changes associated with aquatic adaptations". Science Advances. 5 (9): eaaw6671. Bibcode:2019SciA....5.6671H. doi:10.1126/sciadv.aaw6671. PMC 6760925. PMID 31579821.
  74. Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ (1 January 2009). "Phytomelatonin: a review". Journal of Experimental Botany. 60 (1): 57–69. doi:10.1093/jxb/ern284. PMID 19033551. S2CID 15738948.
  75. Bonnefont-Rousselot D, Collin F (November 2010). "Melatonin: action as antioxidant and potential applications in human disease and aging". Toxicology. 278 (1): 55–67. doi:10.1016/j.tox.2010.04.008. PMID 20417677.
  76. Reiter RJ, Manchester LC, Tan DX (September 2005). "Melatonin in walnuts: influence on levels of melatonin and total antioxidant capacity of blood". Nutrition. 21 (9): 920–4. doi:10.1016/j.nut.2005.02.005. PMID 15979282.
  77. Reiter RJ, Tan DX, Zhou Z, Cruz MH, Fuentes-Broto L, Galano A (April 2015). "Phytomelatonin: assisting plants to survive and thrive". Molecules. 20 (4): 7396–437. doi:10.3390/molecules20047396. PMC 6272735. PMID 25911967.
  78. Arnao MB, Hernández-Ruiz J (September 2015). "Functions of melatonin in plants: a review". Journal of Pineal Research. 59 (2): 133–50. doi:10.1111/jpi.12253. PMID 26094813.
  79. Park S, Lee DE, Jang H, Byeon Y, Kim YS, Back K (April 2013). "Melatonin-rich transgenic rice plants exhibit resistance to herbicide-induced oxidative stress". Journal of Pineal Research. Wiley. 54 (3): 258–63. doi:10.1111/j.1600-079x.2012.01029.x. PMID 22856683. S2CID 6291664.
  80. Arnao MB, Hernández-Ruiz J (December 2014). "Melatonin: plant growth regulator and/or biostimulator during stress?". Trends in Plant Science. Elsevier. 19 (12): 789–97. doi:10.1016/j.tplants.2014.07.006. PMID 25156541. S2CID 38637203.
  81. Arnao MB, Hernández-Ruiz J (September 2015). "Functions of melatonin in plants: a review". Journal of Pineal Research. Wiley. 59 (2): 133–50. doi:10.1111/jpi.12253. PMID 26094813. S2CID 19887642.
  82. Socaciu AI, Ionuţ R, Socaciu MA, Ungur AP, Bârsan M, Chiorean A, et al. (December 2020). "Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases". Reviews in Endocrine & Metabolic Disorders. 21 (4): 465–478. doi:10.1007/s11154-020-09570-9. PMID 32691289. S2CID 220657247.
  83. Burkhardt S, Tan DX, Manchester LC, Hardeland R, Reiter RJ (October 2001). "Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus)". Journal of Agricultural and Food Chemistry. 49 (10): 4898–902. doi:10.1021/jf010321. PMID 11600041.
  84. González-Flores D, Velardo B, Garrido M, González-Gómez D, Lozano M, Ayuso MC, Barriga C, Paredes SD, Rodríguez AB (2011). "Ingestion of Japanese plums (Prunus salicina Lindl. cv. Crimson Globe) increases the urinary 6-sulfatoxymelatonin and total antioxidant capacity levels in young, middle-aged and elderly humans: Nutritional and functional characterization of their content". Journal of Food and Nutrition Research. 50 (4): 229–36.
  85. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S (May 2011). "Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection". Journal of Pineal Research. 50 (4): 374–80. doi:10.1111/j.1600-079X.2010.00853.x. PMID 21342247. S2CID 8034935.
  86. Salehi B (5 July 2019). "Melatonin in Medicinal and Food Plants" (PDF). Cells. 681.
  87. Pereira N, Naufel MF, Ribeiro EB, Tufik S, Hachul H (January 2020). "Influence of Dietary Sources of Melatonin on Sleep Quality: A Review". Journal of Food Science. Wiley. 85 (1): 5–13. doi:10.1111/1750-3841.14952. PMID 31856339.
  88. Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, et al. (March 1995). "Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates". Biochemistry and Molecular Biology International. 35 (3): 627–34. PMID 7773197.
  89. Sae-Teaw M, Johns J, Johns NP, Subongkot S (August 2013). "Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers". Journal of Pineal Research. 55 (1): 58–64. doi:10.1111/jpi.12025. PMID 23137025. S2CID 979886.
Wikimedia Commons has media related to Melatonin.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.